Drug Profile
Research programme: antimalarials - AstraZeneca/MMV
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; Medicines for Malaria Venture
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Malaria in India
- 16 Jul 2016 No recent reports of development identified for research development in Malaria in Switzerland
- 01 Jul 2010 Early research in Malaria in India (unspecified route)